IN2015KN00452A - - Google Patents

Info

Publication number
IN2015KN00452A
IN2015KN00452A IN452KON2015A IN2015KN00452A IN 2015KN00452 A IN2015KN00452 A IN 2015KN00452A IN 452KON2015 A IN452KON2015 A IN 452KON2015A IN 2015KN00452 A IN2015KN00452 A IN 2015KN00452A
Authority
IN
India
Prior art keywords
etanercept
folded
preparations
correctly folded
incorrectly
Prior art date
Application number
Other languages
English (en)
Inventor
Tsutomu Arakawa
Douglas Farrar
Original Assignee
Coherus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50233493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2015KN00452(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Coherus Biosciences Inc filed Critical Coherus Biosciences Inc
Publication of IN2015KN00452A publication Critical patent/IN2015KN00452A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
IN452KON2015 2012-09-11 2013-09-10 IN2015KN00452A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261699552P 2012-09-11 2012-09-11
PCT/US2013/058994 WO2014043103A1 (fr) 2012-09-11 2013-09-10 Étanercept correctement replié de pureté élevée avec un excellent rendement

Publications (1)

Publication Number Publication Date
IN2015KN00452A true IN2015KN00452A (fr) 2015-07-17

Family

ID=50233493

Family Applications (1)

Application Number Title Priority Date Filing Date
IN452KON2015 IN2015KN00452A (fr) 2012-09-11 2013-09-10

Country Status (33)

Country Link
US (6) US20140072560A1 (fr)
EP (1) EP2895188B1 (fr)
JP (3) JP2015533797A (fr)
KR (2) KR102250937B1 (fr)
CN (2) CN104902914B (fr)
AR (1) AR092532A1 (fr)
AU (2) AU2013315750B9 (fr)
BR (1) BR112015005161A2 (fr)
CA (1) CA2882551A1 (fr)
CL (1) CL2015000572A1 (fr)
CO (1) CO7400876A2 (fr)
CY (1) CY1120062T1 (fr)
DK (1) DK2895188T3 (fr)
DO (1) DOP2015000055A (fr)
EA (1) EA031324B1 (fr)
EC (1) ECSP15014138A (fr)
ES (1) ES2657377T3 (fr)
HR (1) HRP20180182T1 (fr)
HU (1) HUE036524T2 (fr)
IL (2) IL237311B (fr)
IN (1) IN2015KN00452A (fr)
LT (1) LT2895188T (fr)
MX (2) MX360044B (fr)
NO (1) NO2972131T3 (fr)
PE (2) PE20150996A1 (fr)
PL (1) PL2895188T3 (fr)
PT (1) PT2895188T (fr)
RS (1) RS57013B1 (fr)
SG (1) SG11201501460RA (fr)
SI (1) SI2895188T1 (fr)
SM (1) SMT201800163T1 (fr)
TW (2) TWI716649B (fr)
WO (1) WO2014043103A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008543839A (ja) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
AU2012326170B2 (en) 2011-10-18 2016-12-22 Coherus Biosciences, Inc. Etanercept formulations stabilized with metal ions
US10485869B2 (en) 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
KR102250937B1 (ko) * 2012-09-11 2021-05-12 코히러스 바이오사이언시즈, 인코포레이티드 고순도 및 탁월한 수율의 정확하게 폴딩된 에타너셉트
WO2015189832A1 (fr) * 2014-06-13 2015-12-17 Lupin Limited Procédé de purification de la protéine de fusion tnfr:fc
EP2975050B1 (fr) 2014-07-18 2019-05-29 Sandoz Ag Quantification de TNFR2:fc mal replié
KR102018608B1 (ko) * 2014-12-31 2019-09-06 주식회사 엘지화학 목적하는 함량으로 불순물을 포함하는 TNFR-Fc 융합 단백질의 제조방법
US20180079796A1 (en) 2015-03-13 2018-03-22 Samsung Bioepis Co., Ltd. Anti-tnf-alpha polypeptide composition and use thereof
CN108350026A (zh) * 2015-11-18 2018-07-31 默克专利股份公司 离子交换色谱法中改进的蛋白质分离
BR112018009882A2 (pt) * 2015-11-18 2018-11-13 Merck Patent Gmbh gradientes de ph-sal opostos para separações melhoradas de proteína
CA3026518A1 (fr) * 2016-06-17 2017-12-21 Genentech, Inc. Purification d'anticorps multispecifiques
ES3064802T3 (en) 2016-10-21 2026-04-29 Amgen Inc Pharmaceutical formulations and methods of making the same
EP3824906A1 (fr) 2016-12-21 2021-05-26 Amgen Inc. Formulations d'anticorps anti-tnf alpha
MX2019011343A (es) * 2017-03-24 2019-11-18 Council Scient Ind Res Un procedimiento para la purificacion de fragmentos de anticuerpos recombinantes.
CA3042126A1 (fr) 2018-05-03 2019-11-03 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methodes de traitement de la maladie de kawasaki
CN112876567A (zh) * 2019-11-29 2021-06-01 广东菲鹏制药股份有限公司 Fc融合蛋白及其纯化方法
AU2021262609A1 (en) 2020-05-01 2022-12-22 Kashiv Biosciences, Llc An improved process of purification of protein
AU2022236913A1 (en) * 2021-03-16 2023-10-26 Kashiv Biosciences, Llc Novel formulation of fusion protein
WO2022234412A1 (fr) * 2021-05-03 2022-11-10 Lupin Limited Procédé de purification de protéines de fusion fc
EP4421089A4 (fr) * 2021-10-19 2026-01-07 Alteogen Inc Procédé de purification d'une protéine de fusion ayant un domaine fc d'igg
US20260159569A1 (en) * 2024-12-06 2026-06-11 Qilu Pharmaceutical Co., Ltd. Variants of etanercept and related processes

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
DE59010908D1 (de) 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
EP0464533B1 (fr) 1990-06-28 1998-07-29 Hoechst Aktiengesellschaft Protéines fusionnées avec des portions d'immunoglobulines, leurs production et utilisation
NZ256293A (en) 1992-09-15 1997-06-24 Immunex Corp Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist
EP0852951A1 (fr) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Compositions pharmaceutiques stables, lyophilisées d'anticorps monoclonaux ou polyclonaux
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
CA2366785C (fr) 1999-04-19 2012-02-07 Immunex Corporation Traitement de troubles d'ordre medical par un recepteur de facteur de necrose tumorale soluble
BR0108193A (pt) 2000-02-10 2003-02-25 Wyeth Corp Processo para tratamento ou inibição de dano celular ou morte celular
US8632778B2 (en) 2000-08-11 2014-01-21 Chugai Seiyaku Kabushiki Kaisha Stabilized anti-interleukin-6 antibody-containing preparations
EE200300408A (et) 2001-02-23 2003-12-15 Immunex Corporation Aktiivsete valkude saagise suurendamine
CA2476934C (fr) * 2002-02-27 2009-06-16 Immunex Corporation Composition stabilisee du fragment fc et du recepteur tnf comprenant de l'arginine
DE60236025D1 (de) * 2002-08-22 2010-05-27 Vasopharm Biotech Gmbh Pharmazeutische zusammensetzung enthaltend l-arginin
US20040115263A1 (en) 2002-08-26 2004-06-17 Robertson David W. Use of bupropion for treating restless legs syndrome
EA009079B1 (ru) 2003-02-28 2007-10-26 Арес Трейдинг С.А. Жидкие составы фактор некроза опухоли-связывающих белков
WO2004082715A1 (fr) 2003-03-20 2004-09-30 Eisai Co., Ltd. Medicament concomitant utilise comme agent therapeutique pour la maladie intestinale inflammatoire
SG145712A1 (en) 2003-08-01 2008-09-29 Amgen Inc Crystalline tumor necrosis factor receptor 2 polypeptides
WO2005037214A2 (fr) 2003-10-14 2005-04-28 Intermune, Inc. Acylsulfonamides et acides carboxyliques macrocycliques utilises en tant qu'inhibiteurs de la replication du virus de l'hepatite c
KR101150050B1 (ko) * 2004-02-27 2012-07-05 지이 헬스케어 바이오-사이언시스 에이비 항체 정제 방법
JP5554466B2 (ja) 2004-03-01 2014-07-23 味の素株式会社 抗ヒトＴＮＦ−α抗体活性低下抑制剤
PL1720972T3 (pl) 2004-03-05 2014-06-30 Dpx Holdings Bv Proces hodowli komórek poprzez ciągłą perfuzję i zmienny przepływ styczny
US20070196364A1 (en) 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
US7300773B2 (en) 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
WO2006122187A2 (fr) 2005-05-10 2006-11-16 Biogen Idec Ma Inc. Traitement et evaluation des troubles inflammatoires
CN101237890A (zh) 2005-06-10 2008-08-06 中外制药株式会社 含有葡甲胺的蛋白质制剂的稳定剂及其利用
TW200738261A (en) 2005-12-20 2007-10-16 Bristol Myers Squibb Co Stable protein formulations
JP5405122B2 (ja) 2005-12-21 2014-02-05 ワイス・エルエルシー 低粘度のタンパク質製剤およびその用途
JP2009525986A (ja) 2006-02-03 2009-07-16 メディミューン，エルエルシー タンパク質製剤
EA015992B1 (ru) 2006-03-17 2012-01-30 Байоджен Айдек Эмэй Инк. Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела
CA2649538C (fr) 2006-04-21 2014-06-03 Yatin Gokarn Agents de tamponnage pour formulations biopharmaceutiques
CA2665567C (fr) 2006-10-06 2012-07-03 Amgen Inc. Formulations stables
US7705132B2 (en) 2006-10-20 2010-04-27 Amgen Inc. Stable polypeptide formulations
MX2009004519A (es) 2006-11-03 2009-05-12 Wyeth Corp Sustancias que inhiben la glucolisis en un cultivo de celulas.
EP2129401B8 (fr) 2006-12-21 2020-01-15 Amgen Inc. Formulations tamponnées stables contenant des polypeptides
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
CA2679941C (fr) 2007-03-02 2016-09-20 Wyeth Utilisation de cuivre et de glutamate dans la culture de cellules pour la production de polypeptides
EP2014760A1 (fr) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S Méthode pour produire un biopolymère (e.g. un polypeptide) pendant un procédé de fermentation continue
CA2690382A1 (fr) 2007-06-14 2008-12-24 Biogen Idec Ma Inc. Formulations d'anticorps
US8420081B2 (en) 2007-11-30 2013-04-16 Abbvie, Inc. Antibody formulations and methods of making same
JP2011514895A (ja) * 2008-02-29 2011-05-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド 精製免疫グロブリン融合タンパク質およびその精製方法
US9238810B2 (en) * 2008-06-05 2016-01-19 Affibody Ab Polypeptide
WO2011015926A1 (fr) * 2009-08-03 2011-02-10 Avesthagen Limited Procédé de fermentation, de purification et de production d’une protéine hybride soluble de recombinaison du récepteur du facteur de nécrose tumorale alpha (tnfr) - domaine fc de l’igg humaine
US8536316B2 (en) 2009-08-07 2013-09-17 Emd Millipore Corporation Methods for purifying a target protein from one or more impurities in a sample
MX355650B (es) 2009-08-11 2018-04-26 Genentech Inc Produccion de proteinas en medios de cultivo de celulas libres de glutamina.
WO2011049798A1 (fr) * 2009-10-20 2011-04-28 Merck Sharp & Dohme Corp. Utilisation de la chromatographie en mode mixte pour la capture et la purification de produits d'anticorps de base
EP2516467A2 (fr) 2009-12-23 2012-10-31 Emergent Product Development Seattle, LLC Compositions comprenant des antagonistes de tnf-alpha et il-6 et leurs procédés d'utilisation
AU2011246503B2 (en) 2010-04-26 2013-09-26 Novartis Ag Improved cell culture medium
RU2600847C2 (ru) * 2010-05-10 2016-10-27 Интас Биофармасьютикалс Лимитед Жидкий состав полипептидов, содержащих fc-домен иммуноглобулина
EP2598167B1 (fr) 2010-07-30 2015-04-01 Arecor Limited Compositions aqueuses stabilisées d'anticorps
EP2606119A1 (fr) 2010-08-20 2013-06-26 Wyeth LLC Culture cellulaire de cellules adaptées exemptes de facteur de croissance
KR20130101034A (ko) 2010-08-31 2013-09-12 프리슬랜드 브랜즈 비브이 진핵 세포를 위한 배양 배지
BR112013008738B1 (pt) * 2010-10-11 2017-12-19 Abbvie Bahamas Ltd. Method for purification of a protein
RU2614257C2 (ru) 2011-04-20 2017-03-24 Сандоз Аг СТАБИЛЬНЫЕ ЖИДКИЕ ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ СЛИТОГО БЕЛКА TNFR:Fc
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
SI2726600T1 (sl) 2011-07-01 2017-07-31 Amgen Inc. Sesalska celična kultura
EA026226B1 (ru) 2011-07-01 2017-03-31 Байоджен Айдек Ма Инк. Не содержащие аргинина композиции слитого fc-полипептида и способы их применения
JP6280499B2 (ja) * 2011-07-08 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｆｃ融合タンパク質の精製方法
ES2651483T3 (es) * 2011-08-17 2018-01-26 Ares Trading S.A. Método para preparar la forma activa de la proteína de fusión TNRF-Fc
US10485869B2 (en) * 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
AU2012326170B2 (en) * 2011-10-18 2016-12-22 Coherus Biosciences, Inc. Etanercept formulations stabilized with metal ions
WO2014011629A1 (fr) * 2012-07-09 2014-01-16 Coherus Biosciences, Inc. Formulations aqueuses stables d'étanercept
KR102250937B1 (ko) * 2012-09-11 2021-05-12 코히러스 바이오사이언시즈, 인코포레이티드 고순도 및 탁월한 수율의 정확하게 폴딩된 에타너셉트
CA2916836C (fr) * 2014-07-31 2017-12-12 Mtt Innovation Incorporated Procedes numeriques de lentilles a forme libre : lentilles a forme libre a zone parametree
US20160108634A1 (en) * 2014-10-16 2016-04-21 Ronald Uphold Pool Cover Hanger Device

Also Published As

Publication number Publication date
BR112015005161A2 (pt) 2017-07-04
US20190300601A1 (en) 2019-10-03
TW201425331A (zh) 2014-07-01
US20190300602A1 (en) 2019-10-03
PL2895188T3 (pl) 2018-06-29
AU2018247244A1 (en) 2018-11-01
US10954295B2 (en) 2021-03-23
MX2015003090A (es) 2015-07-14
DOP2015000055A (es) 2015-04-30
DK2895188T3 (en) 2018-02-26
US20190300600A1 (en) 2019-10-03
MX360044B (es) 2018-10-19
JP2021100929A (ja) 2021-07-08
US20140072560A1 (en) 2014-03-13
HRP20180182T1 (hr) 2018-04-20
IL237311A0 (en) 2015-04-30
TWI609877B (zh) 2018-01-01
RS57013B1 (sr) 2018-05-31
CN104902914A (zh) 2015-09-09
IL267452B (en) 2021-05-31
SI2895188T1 (en) 2018-05-31
KR20200085937A (ko) 2020-07-15
WO2014043103A1 (fr) 2014-03-20
SMT201800163T1 (it) 2018-05-02
EP2895188A1 (fr) 2015-07-22
ES2657377T3 (es) 2018-03-05
MX2018012749A (es) 2020-11-12
US10954293B2 (en) 2021-03-23
HUE036524T2 (hu) 2018-07-30
IL237311B (en) 2019-07-31
EP2895188B1 (fr) 2017-11-15
US11001627B2 (en) 2021-05-11
CY1120062T1 (el) 2018-12-12
AU2013315750A1 (en) 2015-03-05
US20180037642A1 (en) 2018-02-08
AU2018247244B2 (en) 2020-05-28
PE20200607A1 (es) 2020-03-10
CN104902914B (zh) 2019-01-01
AR092532A1 (es) 2015-04-22
PT2895188T (pt) 2018-02-08
JP2019038817A (ja) 2019-03-14
JP2015533797A (ja) 2015-11-26
KR20150056601A (ko) 2015-05-26
EP2895188A4 (fr) 2016-05-25
ECSP15014138A (es) 2016-01-29
CO7400876A2 (es) 2015-09-30
TW201803593A (zh) 2018-02-01
EA031324B1 (ru) 2018-12-28
IL267452A (en) 2019-08-29
TWI716649B (zh) 2021-01-21
US20190330325A1 (en) 2019-10-31
AU2013315750B9 (en) 2018-11-15
CA2882551A1 (fr) 2014-03-20
PE20150996A1 (es) 2015-08-01
CN110051823A (zh) 2019-07-26
JP6913066B2 (ja) 2021-08-04
US10947306B2 (en) 2021-03-16
US10954294B2 (en) 2021-03-23
EA201590542A1 (ru) 2015-07-30
AU2013315750B2 (en) 2018-07-12
KR102133699B1 (ko) 2020-07-14
KR102250937B1 (ko) 2021-05-12
NO2972131T3 (fr) 2018-04-21
LT2895188T (lt) 2018-04-10
SG11201501460RA (en) 2015-04-29
CL2015000572A1 (es) 2016-02-05

Similar Documents

Publication Publication Date Title
MX360044B (es) Etanercept plegado correctamente con alta pureza y un rendimiento excelente.
MX2019003716A (es) Formulaciones farmaceuticas de anticuerpos tnf-alfa.
CY1122165T1 (el) Αντισωματα anti-cd38
IN2014DN10386A (fr)
EA201391240A1 (ru) Слитые белки и комбинированные вакцины, содержащие белок е и пилин а haemophilus influenza
MX2019006045A (es) Proteinas triespecificas dirigidas a psma y metodos de uso.
MX2015000813A (es) Composiciones liposómicas de inhibidores de proteasoma basadas en epoxicetona.
IN2015DN00847A (fr)
WO2012174487A8 (fr) Inhibiteurs à bromodomaine et leurs utilisations
WO2012151512A3 (fr) Inhibiteurs de bromodomaines et leurs utilisations
MX2013000958A (es) Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma.
TR201905619T4 (tr) Alerji aşısı olarak peptit taşıyıcı füzyon proteinleri.
EA201391515A1 (ru) Инактивированная вакцина вируса денге
MX2014004359A (es) Proteina naglu humana recombinante y usos de la misma.
MX2014004814A (es) Compuestos y metodos para mejorar las respuestas inmunes innatas.
MX2021013665A (es) Proteinas de union a calicreina en plasma y usos de las mismas para tratar el angioedema hereditario.
MX339666B (es) Composiciones y metodos para estabilizar formulaciones que contienen proteinas.
MX387764B (es) Procedimiento de disminucion de la inmunogenicidad de proteinas y peptidos.
MD20150109A2 (ro) Construcţii proteice mitocondriale şi utilizările acestora
EA201792608A2 (ru) Применение белков p3 бактериофага в качестве агентов, связывающих амилоид
ZA201308460B (en) Preparation of soy protein isolate using calcium chloride extraction ("s703 cip")
MX2020011825A (es) Compuestos organicos.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
FI20115374A0 (fi) Uudet hypoallergeenit
AU2012280776B2 (en) Compounds and pharmaceutical combinations for the treatment of neurodegenerative and ischemic brain diseases